Reset
Showing 7 of 7 academic articles

Immunoinformatics and Reverse Vaccinology Approach for the Identification of Potential Vaccine Candidates against <i>Vandammella animalimors</i>

Ahmad Hasan, Wadi B. Alonazi, Muhammad Ibrahim, Li Bin • Microorganisms (2024)

Vandammella animalimorsus is a Gram-negative and non-motile bacterium typically transmitted to humans through direct contact with the saliva of infected animals, primarily through biting, scratches, or licks on fractured skin. The absence o...

DOAJ Open Access (DOAJ) DOI: 10.3390/microorganisms12071270

Protocol to measure human IL-6 secretion from CAR T cell-primed macrophage and monocyte lineage cells in vitro and in vivo using humanized mice

Thao Nguyen, Toshiaki Yoshikawa, Yusuke Ito, Hitomi Kasuya et al. • STAR Protocols (2024)

Summary: Chimeric antigen receptor (CAR) T cell therapy often causes serious toxicities, such as cytokine release syndrome (CRS), mainly due to interleukin-6 (IL-6) secreted by monocyte lineage cells. Here, we describe a protocol to generat...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.xpro.2024.103423

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer (2024)

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...

DOAJ Open Access (DOAJ) DOI: 10.1136/jitc-2023-008450

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration

Katie S. Gatwood, Bhagirathbhai R. Dholaria, Mariana Lucena, Brittney Baer et al. • eJHaem (2022)

Abstract Adoptive cellular therapy has made a landmark change within the treatment paradigm of several hematologic malignancies, and novel cellular therapy products, such as chimeric antigen receptor T‐cell therapy (CART), have demonstrated...

DOAJ Open Access (DOAJ) DOI: 10.1002/jha2.333

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena et al. • Frontiers in Immunology (2025)

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successe...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2024.1489827

Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CARNK cells

Katharina Schindler, Katharina Eva Ruppel, Claudia Müller, Ulrike Koehl et al. • Molecular Therapy: Methods & Clinical Development (2024)

Chimeric antigen receptor (CAR) T cell therapies have demonstrated significant successes in treating cancer. Currently, there are six approved CAR T cell products available on the market that target different malignancies of the B cell line...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.omtm.2024.101328